- slider1.jpg
- slider1.jpg
- slider1.jpg
- slider1.jpg
- slider1.jpg
- slider1.jpg
WORKING TO SAVE LIVES
CytoSorb® is a unique blood purification therapy to control deadly inflammation in life-threatening illnesses in the ICU and cardiac surgery. The product is currently approved in the European Union and distributed in 75 countries around the world.
THE POWER OF THE BEAD
Powered by massive surface area, our purification technologies are based on biocompatible, highly porous polymer beads that can actively remove excessive cytokines and other inflammatory mediators from blood and other bodily fluids by pore capture and surface adsorption.
INFORMATION FOR INVESTORS
CytoSorbents specializes in treating life-threatening conditions in the ICU and during open heart surgery. Â The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders.
Recent News
- CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry
- CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
- CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation
- CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico
- CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
- slider1.jpg
